SURVEY REVEALS KEY FACTORS IN PATIENT EXPERIENCE
You and your staff have a significant impact on patient satisfaction.
A new survey from practice technology company ModMed revealed that patients considered factors such as timeliness, friendliness of the staff and the use of modern technology so important to the overall experience that they seek out a new doctor if those needs are not met.
According to the survey, 73% of patients are somewhat likely or very likely to keep a “mental scorecard” of all the things they like and dislike about a new doctor’s office. Doctors’ offices are given, on average, four chances before a patient decides to find a new doctor.
The survey, conducted by the research firm OnePoll, asked 2,000 patients about their experience with a doctor’s office and showed that even with digital options available, human interaction remains important. For example, when deciding to see the same doctor, 67% of patients polled rated how personable and engaged a doctor is either very important or somewhat important.
“All of us [MDs] are essentially delivering the same diagnostics and treatments. The difference between doctors is often how personable they are and how they connect with their patients,” says Jonathan Feistmann, MD, NYC Retina in New York.
VALUE OF FRIENDLY STAFF
Staff are also a key aspect of the patient experience. According to the survey, one out of three patients have switched doctors due to unfriendly staff. “Every interaction is an opportunity for your staff to make that experience even better,” Dr. Feistmann says.
Regarding staff, 75% of the survey respondents considered staff friendliness to be somewhat important or very important in the waiting room. In addition, 65% report staff friendliness is important when considering whether to see the same doctor as before.
“MDs should explain to their staff how important they are to the patient experience,” says Andrew Miller, MD, Associates in Ophthalmology, Livingston, N.J. “They are the first and last impression that a patient gets from the practice. Patients often tell me that they consider how the staff treats patients as a reflection of the doctors.”
THE BENEFITS OF TECHNOLOGY
In addition, the survey provides insights into patients’ perspectives on a practice’s website, online reviews, waiting room, staff, payments process, follow-up communications and more. It also inquired about which digital tools patients prefer to use before, during and after a medical visit.
For example, 60% of patients are somewhat likely or very likely to select one doctor over another if able to make appointments online. And 61% place importance on how easy it is to make payments when considering whether to continue seeing a doctor.
“We find there are certain things that need to be done in person or over the phone,” says Dr. Feistmann. “However, for anything else that can be automated, we try to take advantage of technology to make the process easier for patients and less burdensome on staff. Appointment requests and reminders and patient payment are excellent examples of this.”
In addition to making transactions easier, digital tools can impact the perception of quality of care: For example, 89% of respondents strongly agree or somewhat agree that the office staff seems more engaged since introducing new technology at the office. Digital tools can also help make staff more productive.
“Taking a digital-first approach with patients could free up staff to focus more on non-administrative tasks, giving them more time to focus on patients and potentially boosting their own job satisfaction,” says Daniel Cane, CEO, at ModMed.
In the exam room, 46% prefer their doctor use a tablet to review patient history, and 54% strongly agree that their doctor seems more attentive with the introduction of new technology.
“I often get compliments from patients that they appreciate the up-to-date technology in our office. It makes them feel confident they are getting the best care,” says Dr. Feistmann.
BE ACCESSIBLE TO PATIENTS
According to the survey, most patients agree that it’s somewhat frustrating or very frustrating when they call for an appointment and have to leave a voicemail and wait to be called back. In fact, a combined 48% prefer to email, text or use an online portal over a phone call to make appointments. In addition, 67% are much more likely or somewhat more likely to use chat vs calling to make an appointment or request lab results. And 59% of those surveyed report frustration in playing phone tag with the staff.
“The more that your staff is accessible to patients, the better,” Dr. Feistmann says. “Communication is key for customer service. In addition to medical care, communication, when done well, is what makes people feel well taken care of by staff and doctors.”
For more information, download the report, ModMed 2022 Patient Experience Report: What Patients Really Think, available at modmed.com . OM
A version of this article previously ran in Ophthalmic Professional.
IN THE NEWS:
Alcon and Aerie Pharmaceuticals announced the companies have entered into a definitive merger agreement through which Alcon will acquire Aerie. Alcon will add the commercial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%. Alcon will also add AR-15512, a Phase 3 product candidate for dry eye disease, and a pipeline of several clinical/preclinical ophthalmic pharmaceutical product candidates.
Retina and multi-specialty ophthalmology practices will now be able to synchronize data and share documents between the ModMed all-in-one ophthalmology solution and SamaCare’s prior authorization management platform. The partnership is aimed to reduce administrative workload and prevent human errors caused by manual data entry between systems.
Sight Sciences launched the SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. Sight Sciences also released 36-month post-surgery follow-up results of the OMNI Surgical System that demonstrated the system’s safety, consistency and durability in adult patients with open-angle glaucoma on a standalone basis.
AbbVie and iSTAR Medical SA announced a strategic transaction to further develop and commercialize iSTAR’s MINIject device, a minimally invasive glaucoma surgical device for patients with glaucoma. The complementary alliance will support iSTAR’s development and commercial efforts for MINIject, as well as provide an opportunity to expand AbbVie’s eye-care business. AbbVie will hold the exclusive right to acquire iSTAR and lead subsequent global development and commercialization of the MINIject device.
Coherus BioSciences announced the FDA approved CIMERLI (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis (ranibizumab injection) for all five indications, meeting the FDA’s standards to the reference product, including safety, efficacy and quality. Commercial availability of CIMERLI, in both 0.3-mg and 0.5-mg dosages, is planned for October 2022.
eSight and Marathon Medical, a Service-Disabled Veteran Owned Small Business certified distributor to veteran medical facilities across the United States, announced a partnership to provide eSight 4 advanced all-in-one wearable assistive eyewear medical devices for people with central vision loss to the U.S. Department of Veterans Affairs’ national health-care system.
iHealthScreen Inc. completed the first prospective clinical study on AI and color retinal image-based early diagnosis of AMD in outpatient settings. Initial results from the study showed that the AMD screening tools achieved above 88% accuracy. iHealthScreen is in the final stage of submitting the results to the FDA for 510K clearance.
Alimera Sciences’ PALADIN Phase 4 Study demonstrated the safety of ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg sustained-release intravitreal implant and that it is a durable treatment option to reduce the frequency of recurrence for patients with diabetic macular edema. The study showed the benefit of using a prior course of corticosteroid to mitigate the risk of uncontrolled IOP elevations.
IVERIC bio reported positive topline results from GATHER2, the company’s second Phase 3 clinical trial of Zimura (avacincaptad pegol), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA). GATHER2 met its prespecified primary endpoint with 14.3% reduction (p-value=0.0064) in mean rate of growth (Slope) in GA area over 12 months using square root transformation, 17.7% reduction (p-value=0.0039) using observed GA Area.
Apellis Pharmaceuticals reported top-line data at 24 months showing increased effects over time with intravitreal pegcetacoplan, an investigational, targeted C3 therapy, in the Phase 3 DERBY and OAKS studies in GA secondary to AMD. In a pre-specified analysis of GA lesion growth over 24 months, both monthly and every-other-month pegcetacoplan showed a clinically meaningful reduction in GA lesion growth from baseline compared to sham.
Formosa Pharmaceuticals and AimMax Therapeutics reported top-line results from CPN-302, the second of two pivotal Phase 3 clinical studies of APP13007, a novel ophthalmic nanosuspension formulation of the corticosteroid, clobetasol propionate (0.05%), for the treatment of inflammation and pain after cataract surgery. Both primary endpoints were achieved, producing rapid and sustained clearance of ocular inflammation and cure of ocular pain.